Second Partner Exercises Option for Exclusive Period to Negotiate Licensing Terms for CeraShield Antimicrobial Coating Application

DENVER--(Business Wire)--
Ceragenix Pharmaceuticals, Inc. ("Ceragenix" or the "Company") (OTCBB:CGXP), a
medical device company focused on infectious disease and dermatology, today
provided an update to a previously announced exclusive cooperative research and
development (the "Agreement") with MAST BioSurgery Inc. ("MAST") for the
development of one or more new surgical products incorporating Ceragenix`s
CeraShield antimicrobial technology. Ceragenix announced that based on its
evaluation activities undertaken to-date, MAST has decided to invoke its right
to negotiate commercialization terms pursuant to the terms of the Agreement.
Under the terms of the Agreement, MAST has an exclusive sixty (60) day period to
negotiate a license agreement for the Cerashield technology within the field of
use as defined in the Agreement. There is no assurance that the parties will be
able to reach an agreement on the terms of a license agreement.

Mr. Steven Porter, Chairman and CEO of Ceragenix said: "We're very pleased to
announce this progress in our licensing efforts. MAST represents the second
partner to exercise their exclusive option to license rights within the past two
months. We look forward to our discussions with MAST on how we can move forward
together."

About Ceragenix

Ceragenix Pharmaceuticals, Inc. is a medical device company focused on
infectious disease and dermatology. The Company has two base technology
platforms; Ceragenins for treatment of infectious disease and Barrier Repair for
the treatment of dermatological disorders including atopic dermatitis, neonatal
skin disorders and others. Ceragenin compounds are active against a broad range
of gram positive and negative bacteria. We have used our Ceragenin technology to
formulate Cerashield antimicrobial coatings for medical devices. All Ceragenin
and Cerashield products are currently in the developmental stage. Ceragenix's
patented Barrier Repair technology, invented by Dr. Peter Elias, is the platform
for the development of EpiCeram which is currently being marketed by Promius
Pharmaceuticals (a wholly owned subsidiary of Dr. Reddy's Laboratories) in the
United States under an exclusive supply and distribution agreement. For
additional information on Ceragenix, please visit www.ceragenix.com.

About Mast

MAST Biosurgery, Inc. is a wholly owned subsidiary of privately held MAST
Biosurgery AG. MAST Biosurgery, Inc. was founded in 2004 in San Diego, Calif.,
and is an industry leader in the design, development and production of
bioresorbable thin film implants for use in a wide variety of surgical
specialties. For more information about MAST Biosurgery, Inc., please visit
www.mastbio.com.

FORWARD LOOKING STATEMENTS FOR CERAGENIX.

This press release may contain forward-looking statements. These forward-looking
statements are subject to risks and uncertainties that may cause actual results
to differ materially from those expressed or implied by such forward-looking
statements, including, but not limited to, the following: the ability of the
Company to fund its operations beyond November 2009; the ability of the Company
to successfully negotiate an exclusive license agreement with its partner; the
ability of our partner to successfully develop a product using the Cerashield
technology; the ability of the Company to raise sufficient capital to finance
its operations and planned activities including completing development of its
Ceragenin technology; the ability of the Company to meet its obligations under
the supply and distribution agreement with Dr. Reddy's Laboratories including
having sufficient working capital to fulfill purchase orders within the
timeframes required by the agreement; the ability of the Company to service its
outstanding convertible debt obligations; receiving the necessary marketing
clearance approvals from the United States Food and Drug Administration (the
"FDA"); successful clinical trials of the Company's planned products including
the ability to enroll the studies in a timely manner, patient compliance with
the study protocol, and a sufficient number of patients completing the studies;
the ability of the Company to commercialize its planned products; the ability of
the Company to successfully manufacture its products in commercial quantities
(through contract manufacturers); market acceptance of the Company's planned
products, the Company's ability to successfully develop its licensed compounds,
alone or in cooperation with others, into commercial products, the ability of
the Company to successfully prosecute and protect its intellectual property,
general economic conditions in the United States and elsewhere, and the
Company's ability to hire, manage and retain qualified personnel. The
aforementioned factors do represent an all inclusive list. Actual results,
performance or achievements could differ materially from those contemplated,
expressed or implied by the forward-looking statements contained in this press
release. In particular important factors that could cause actual results to
differ materially from our forward-looking statements including general economic
factors, business strategies, the state of capital markets, regulatory
conditions, and other factors not currently known to us, may be significant, now
or in the future, and the factors set forth in this press release may affect us
to a greater extent than indicated. All forward-looking statements attributable
to us or persons acting on our behalf are expressly qualified in their entirety
by the cautionary statements set forth in this press release and in other
documents that we file from time to time with the Securities and Exchange
Commission including its Annual Report on Form 10-K for the year ended December
31, 2008, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K to be
filed in 2009. Except as required by law, we do not undertake any obligation to
update any forward-looking statement, whether as a result of new information,
future events or otherwise.

Ceragenix Pharmaceuticals, Inc.
Steven Porter, 720-946-6440
Chairman and CEO

Copyright Business Wire 2009